Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
10.12016/j.issn.2096-1456.2021.10.010
- Author:
ZENG Fei
1
;
LU Jie
1
;
SUN Renhao
2
;
FANG Yikang
2
;
YU Wenyi
3
;
YANG Fang
3
;
ZHAO Lu
3
Author Information
1. 1. Dalian Medical University School of Stomatology 2. Qingdao Municipal Hospital Stomatology Center
2. 1. Dalian Medical University School of Stomatology 2. Qingdao Municipal Hospital Stomatology Center
3. Qingdao Municipal Hospital Stomatology Center
- Publication Type:Review
- Keywords:
head and neck squamous cell carcinoma;
programmed death receptor 1;
programmed death receptor ligand 1;
immunotherapy;
programmed death receptor 1 inhibitor;
programmed death receptor ligand 1 inhibitor;
Nivolumab;
Pembrolizumab;
Durvalumab;
Atezolizumab
- From:
Journal of Prevention and Treatment for Stomatological Diseases
2021;29(10):706-710
- CountryChina
- Language:Chinese
-
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues.
- Full text:程序性死亡受体-1及其配体抑制剂在头颈部鳞状细胞癌免疫治疗的研究进展.pdf
